Thermo Fisher Scientific Inc. $TMO Position Boosted by Evergreen Private Wealth LLC

Key Points

• Evergreen Private Wealth LLC has increased its holdings in Thermo Fisher Scientific by 15.7%, owning a total of 12,798 shares valued at approximately $5.19 million.
• Multiple institutional investors, including GAMMA Investing LLC and Nuveen LLC, have significantly increased their stakes in Thermo Fisher, showcasing a strong institutional interest with 89.23% of the stock owned by such investors.
• Analysts have a consensus rating of "Moderate Buy" for Thermo Fisher Scientific, with an average target price of $588.35, reflecting positive market sentiment.

Evergreen Private Wealth LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 15.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,798 shares of the medical research company's stock after buying an additional 1,740 shares during the quarter. Thermo Fisher Scientific comprises 2.2% of Evergreen Private Wealth LLC's portfolio, making the stock its 19th largest holding. Evergreen Private Wealth LLC's holdings in Thermo Fisher Scientific were worth $5,189,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TMO. GAMMA Investing LLC grew its holdings in Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after buying an additional 2,415,346 shares in the last quarter. Nuveen LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth approximately $532,360,000. Sarasin & Partners LLP bought a new position in Thermo Fisher Scientific in the 1st quarter worth approximately $242,991,000. EdgePoint Investment Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $172,139,000. Finally, Cohen Investment Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 6,655.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock worth $167,271,000 after buying an additional 331,180 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TMO. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Evercore ISI dropped their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Robert W. Baird boosted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. HSBC reissued a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. Sixteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average target price of $588.35.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the transaction, the chief executive officer owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO opened at $459.34 on Friday. The stock has a fifty day moving average of $475.73 and a 200-day moving average of $448.37. The firm has a market capitalization of $173.45 billion, a P/E ratio of 26.57, a PEG ratio of 2.54 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $623.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.